📋 Pep IQ provides independent reference information for educational purposes only. Nothing here constitutes medical advice or treatment recommendation. All compounds require individual assessment. Consult a qualified physician before considering any peptide protocol.
Myostatin Inhibitor Muscle Mass Peptide

Follistatin

FST · Follistatin-315 · Follistatin-344 · Myostatin Antagonist

"The natural brake-release for muscle growth. Myostatin keeps your muscles from growing beyond a set point — follistatin blocks it. Animals without myostatin have twice the muscle mass. A Phase 1 clinical trial in muscular dystrophy patients showed significant strength improvements. The most potent muscle-growth mechanism known."

Type
Myostatin + activin A antagonist
Animal data
2× muscle mass in myostatin-null mice · pronounced primate gains
Status
UK: not illegal to buy or possess · WADA: prohibited (myostatin inhibitor class) · US FDA: not approved · Phase 1 gene therapy trial in Becker MD · no peptide RCTs
Key concern
Use FS315 isoform — FS288 risks FSH suppression
Protocol summary
Community dose
100–200 mcg/day SubQ
Cycle
10–30 days · 3–4 wks off
Frequency
1–3 cycles/year
Community-reported
100–200 mcg/day SubQ · 10–30 day cycles · choose FS315 isoform to avoid FSH suppression
No peptide-form RCTs — all human evidence is from gene therapy trials in muscular dystrophy
How we read the evidence
Strong primate gene therapy data · zero peptide-form RCTs · myostatin biology is real, peptide injection evidence is not
Animal evidence

Substantial preclinical evidence for follistatin biology. Transgenic mice overexpressing follistatin show striking muscle mass increases. Kota et al. 2009 (Science Translational Medicine) demonstrated AAV-delivered follistatin gene therapy enhanced muscle growth and strength in nonhuman primates. Long-term enhancement of skeletal muscle via single gene administration was published in PNAS 2008. The mechanism (myostatin and activin neutralisation) is well-characterised and conserved across mammalian species — Belgian Blue cattle and certain whippets demonstrate the natural muscle hypertrophy phenotype when myostatin signalling is reduced.

Community & clinical practice

Community injection protocols converge on 100–200 mcg SubQ daily for 10–30 day cycles, with 3–4 weeks off, repeated 1–3 times per year. Some bodybuilding protocols use 50 mcg IM 30 minutes pre-training, training days only, 8 weeks on/8 weeks off. Practitioners typically start conservatively at 100 mcg/day for a 10-day cycle to assess response. Local injection (deltoid, quad) for site-specific effects is reported anecdotally; systemic via SubQ is the more common approach.

Human trial data

No published controlled human trials for the injectable peptide form. The only human follistatin clinical data comes from gene therapy — a Phase 1/2a trial for Becker muscular dystrophy delivered FS-344 via AAV vector, and an ongoing Phase 1 plasmid gene therapy trial (NCT06411366) for frailty/aging at the Roatan Global Alliance for Regenerative Medicine site. Earlier myostatin-inhibition trial (MYO-029, recombinant antibody) showed small dose-related muscle mass increase but no functional strength benefit in muscular dystrophy patients. Translation from gene therapy (sustained follistatin expression over months) to short peptide cycles is not established.

Regulatory status

Not FDA-approved. WADA-banned for tested athletes — explicitly listed as a banned myostatin-inhibiting agent. Sourcing via research-peptide vendors only. Fragile compound — reconstitution and storage requirements are stricter than most peptides. Theoretical concerns include fertility effects (follistatin also binds activin, affecting FSH regulation) — exit cycles and post-cycle monitoring are common community practice.

Convergence

Follistatin is the most direct myostatin inhibition outside of gene therapy. The biology is real and well-evidenced; the peptide injection evidence is not. Community protocols (100–200 mcg/day × 10–30 days, 1–3× yearly) are extrapolated from gene therapy data and animal models without controlled human peptide trial validation. Pep IQ flags this honestly: the underlying mechanism has Phase 1/2a gene therapy data, but the injectable peptide protocols people are running are based on extrapolation. Cost is high, evidence is thin, fertility concerns are real, and effects do not approach what gene therapy achieves.

Origin & Background

Taking the brake off muscle growth

Follistatin is a naturally occurring glycoprotein — not an exogenous drug — that every human body produces as a regulator of growth factor signalling. Its primary pharmacological role is binding and neutralising myostatin (GDF-8) and activin A, both members of the TGF-β superfamily that suppress muscle growth and increase fat deposition. When myostatin binds to its muscle receptor (ActRIIB), it signals muscles to stop growing. Follistatin prevents this signal.

The extraordinary potential of this mechanism was revealed by myostatin knockout animals: mice without myostatin have twice the normal muscle mass through a combination of fibre hypertrophy and hyperplasia. A child with a naturally occurring myostatin mutation was documented with extraordinary muscular development. Follistatin-overexpressing transgenic mice show muscle mass increases of 30-37% beyond even myostatin-null levels — because follistatin also blocks activin A and other TGF-β members in addition to myostatin alone.

Two key isoforms exist: FS-288 (membrane-bound, high activin affinity, FSH-suppressing) and FS-315 (circulating, lower activin affinity, minimal reproductive effects). The critical safety innovation is using the FS-344 cDNA (which produces FS-315) rather than FS-317 (which produces FS-288) — avoiding FSH suppression and reproductive system off-target effects. The Nationwide Children's Hospital gene therapy programme, using AAV1.FS-344, has advanced through primate studies to Phase 1 human trials in Becker muscular dystrophy.

Gene therapy vs peptide: The most clinically advanced follistatin research uses AAV-delivered gene therapy — a single injection expressing the FS-344 gene, producing FS-315 for up to 15 months. Direct injection of recombinant follistatin peptide is a different and less well-characterised approach. Minicircle has a commercial follistatin plasmid therapy in 500+ patients. The injectable research peptide used in biohacking contexts is distinct from all of these.

Science & Mechanism

Dual blockade — myostatin and activin A

Mechanism of Action

1
Myostatin neutralisation: Follistatin binds myostatin directly, preventing it from interacting with its muscle receptor ActRIIB. Without ActRIIB activation, the downstream SMAD2/3 phosphorylation cascade that suppresses muscle protein synthesis cannot proceed. Myostatin can no longer limit muscle fibre size.
2
Activin A blockade (the critical second mechanism): Follistatin also inhibits activin A, another muscle-suppressing TGF-β family member. Follistatin overexpression in myostatin-null mice still produced 37% additional muscle mass — demonstrating that activin A blockade contributes independent muscle growth beyond myostatin inhibition alone. Drugs targeting only myostatin miss this.
3
Satellite cell activation: Follistatin promotes satellite cell (muscle stem cell) proliferation — the mechanism by which muscle fibres regenerate after damage. Irradiated muscles with impaired satellite cell function showed reduced (20% vs 37%) follistatin-induced hypertrophy, confirming the satellite cell contribution is significant but not the only mechanism.
4
Anti-inflammatory effects: Follistatin reduces inflammation in endotoxemia models independently of its muscle effects. This systemic anti-inflammatory property may explain some of the broader health benefits reported in gene therapy recipients beyond muscle mass alone.
5
Self-limiting feedback: After peak increase at 12 weeks, muscle growth rate stabilises — a built-in feedback mechanism prevents uncontrolled hypertrophy. This "set-point stabilisation" is seen in both gene therapy models and myostatin-null animals, suggesting the body has compensatory mechanisms that limit excessive muscle growth.

The primate data (cynomolgus macaques, Nationwide Children's Hospital) is particularly important: AAV1.FS-344 produced pronounced and durable increases in muscle size and strength after quadriceps injection, maintained for 15 months without abnormal changes in organ morphology or function. The first human Phase 1 trial in Becker muscular dystrophy (6 patients, bilateral quadriceps injection): patients 01 and 02 improved 58m and 125m respectively on the 6-minute walk test — clinically meaningful improvements in a condition with no existing treatment.

Benefits & Evidence

What the data shows

💪
Muscle mass — extraordinary animal data
Myostatin-null mice: 2× muscle mass. FS overexpression transgenic mice: +37% beyond myostatin-null. AAV1.FS-344 in rats: +37% muscle weight at 17 days. Non-human primates (macaques): pronounced durable muscle size and strength increase at 15 months. No serious adverse effects on key organs in primate studies.
● Strong animal + primate · Phase 1 human
🏥
Functional improvement — muscular dystrophy
Phase 1 BMD trial: bilateral intramuscular injection in 6 patients. Patients 01 and 02: +58m and +125m on 6-minute walk test. The distance walked is a primary outcome measure for Becker MD — these are clinically meaningful improvements in a disease with no approved treatment.
● Moderate — Phase 1 proof-of-concept · n=6
⚖️
Body composition (gene therapy)
Minicircle plasmid therapy (500+ patients): lean mass increases, fat mass decreases, 12-year epigenetic age reduction reported in aged participants. Slight LDL increase in ~1/3. These are observational data from a commercial programme — not controlled RCT data.
● Limited — observational · commercial programme
Things to know

Risks & considerations

⚠️
The FS-315 isoform (from FS-344 gene) is safe in primates and humans — but the FS-288 isoform suppresses FSH and has reproductive effects. The key safety decision in clinical follistatin research was always using FS-344 (which produces FS-315, the circulating form) not FS-317 (which produces FS-288, the cell-surface/gonadal form). Research peptide sources may not specify which isoform is supplied.
Serious
FSH suppression (FS-288 isoform only): FS-288 has 10× higher affinity for activin than FS-315 and targets gonadal tissue, suppressing follicle-stimulating hormone — potentially causing reproductive dysfunction. Critical to confirm which isoform you are using.
Mild
Mild LDL increase — approximately 1/3 of Minicircle participants showed a slight LDL increase (~8mg/dL). The mechanism is unclear but may relate to activin A's role in lipid metabolism.
Unknown
Long-term human safety of injected recombinant peptide — the gene therapy and plasmid therapy approaches have growing safety databases. Direct injection of recombinant follistatin peptide does not. Isoform, dose, and delivery vehicle all affect the risk profile.
Moderate
Uncontrolled muscle growth theoretical risk — in practice, the built-in feedback mechanisms prevent runaway hypertrophy. No cases of problematic uncontrolled muscle growth have been reported in human subjects. The self-limiting mechanism appears robust.
Fast Facts
MechanismMyostatin + activin A dual blockade
Key isoformFS-315 (from FS-344) — safe circulating form
AvoidFS-288 / FS-317 — FSH suppression risk
Animal data2× muscle mass in myostatin-null mice
Primate dataDurable muscle + strength · 15 months
Human dataPhase 1 BMD · +58-125m walk test
DeliveryGene therapy · plasmid · injectable peptide (research)
Related Peptides
IGF-1Complementary anabolic pathway
HGH (full chain)GH-axis muscle growth comparison
MK-677Oral GH approach to muscle mass
BPC-157Tissue repair complement